Axovant Sciences Ltd (AXON) to Release Earnings on Monday
Axovant Sciences Ltd (NYSE:AXON) will post its quarterly earnings results before the market opens on Monday, November 6th. Analysts expect Axovant Sciences to post earnings of ($0.58) per share for the quarter.
Axovant Sciences (NYSE:AXON) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.12). On average, analysts expect Axovant Sciences to post $-2.02 EPS for the current fiscal year and $-2.07 EPS for the next fiscal year.
Axovant Sciences Ltd (AXON) opened at 5.13 on Monday. The firm’s market capitalization is $551.60 million. Axovant Sciences Ltd has a 52 week low of $4.60 and a 52 week high of $27.98. The stock’s 50 day moving average is $11.81 and its 200-day moving average is $19.55.
TRADEMARK VIOLATION WARNING: “Axovant Sciences Ltd (AXON) to Release Earnings on Monday” was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.americanbankingnews.com/2017/10/30/axovant-sciences-ltd-axon-to-release-earnings-on-monday-2.html.
AXON has been the topic of several recent research reports. BidaskClub downgraded shares of Axovant Sciences from a “sell” rating to a “strong sell” rating in a research report on Friday, September 15th. Evercore ISI initiated coverage on shares of Axovant Sciences in a research report on Friday, September 8th. They issued an “outperform” rating and a $30.00 price objective on the stock. Zacks Investment Research upgraded shares of Axovant Sciences from a “hold” rating to a “strong-buy” rating and set a $8.00 price objective on the stock in a research report on Monday, October 9th. Chardan Capital reiterated a “sell” rating and issued a $3.00 price objective on shares of Axovant Sciences in a research report on Saturday, September 23rd. Finally, Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $30.00 price objective on shares of Axovant Sciences in a research report on Monday, September 25th. Four analysts have rated the stock with a sell rating, four have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Axovant Sciences has a consensus rating of “Hold” and an average price target of $14.13.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.